Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talabostat - BioXcel Therapeutics

Drug Profile

Talabostat - BioXcel Therapeutics

Alternative Names: BXCL 701; PT-100; Talabostat mesilate; Talabostat mesylate; Val-boro-Pro

Latest Information Update: 18 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tufts University School of Medicine
  • Developer BioXcel Therapeutics; Georgetown University; M. D. Anderson Cancer Center; Midatech Pharma US; National Cancer Institute (USA); OnkosXcel Therapeutics
  • Class Antineoplastics; Boronic acids; Dipeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Dipeptidyl peptidase 8 inhibitors; Dipeptidyl peptidase 9 inhibitors; Fibroblast activation protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Pancreatic cancer; Malignant melanoma; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Prostate cancer
  • Phase I/II Pancreatic cancer
  • Phase I Acute myeloid leukaemia
  • Preclinical Small cell lung cancer
  • Suspended Myelodysplastic syndromes; Soft tissue sarcoma; Solid tumours
  • Discontinued Chronic lymphocytic leukaemia; Malignant melanoma; Neutropenia; Non-small cell lung cancer

Most Recent Events

  • 18 Apr 2024 BioXcel Therapeutics anticipates a meeting with FDA regarding development of talabostat in Prostate cancer (small cell neuroendocrine prostate cancer) in 2024
  • 18 Apr 2024 BioXcel Therapeutics plans a phase Ib/II trial for Small cell lung cancer in 2024
  • 28 Mar 2024 Suspended - Phase-I for Myelodysplastic syndromes (In the elderly, In adults, Second-line therapy or greater, Refractory metastatic disease) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top